BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 18, 2024
Home
»
Newsletters
» BioWorld
BioWorld
April 25, 2003
View Archived Issues
Genzyme Wins FDA Approval For Fabry's Disease Treatment
Genzyme General received FDA approval of the orphan drug Fabrazyme, an enzyme replacement therapy for a rare, genetic disorder called Fabry's disease. (BioWorld Today)
Read More
High Revenues Drive Earnings Growth At Biotech Bellwethers
Read More
Coated Magnetic Beads Take Over Dendritic Cell's Flagging Down Of Invasive Antigens For Destruction
Read More
FDA Clears Path For Phase III; NeoRx Stock Soars On News
Read More
Correction
Read More
Thompson Pushes Administration Initiatives In Science Forum Talk
Read More
Other News To Note
Read More